1. Generics Bulletin
  2. >>Products

Endo’s Par Delivers On Nevakar Alliance With First Launch

Launch Of Pre-Mixed Ephedrine Sulfate Follows 2018 Deal With 505(b)(2) Specialist

 
• By Dave Wallace

Endo’s Par has announced the first launch under a longstanding US collaboration with 505(b)(2) specialist Nevakar, in the form of pre-mixed ephedrine sulfate injection in a ready-to-use 50mg/10ml single-use vial.

black chalk board with lettering ephedrine
Pre-mixed ephedrine sulfate is the first launch through Endo’s alliance with Nevakar • Source: LightField Studios Inc. / Alamy Stock Photo

Endo has delivered on its alliance with US 505(b)(2) injectables specialist Nevakar by launching pre-mixed ephedrine sulfate injection in a ready-to-use 50mg/10ml single-use vial.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.